IL101229A0 - Compositions for accelerated wound healing - Google Patents

Compositions for accelerated wound healing

Info

Publication number
IL101229A0
IL101229A0 IL101229A IL10122992A IL101229A0 IL 101229 A0 IL101229 A0 IL 101229A0 IL 101229 A IL101229 A IL 101229A IL 10122992 A IL10122992 A IL 10122992A IL 101229 A0 IL101229 A0 IL 101229A0
Authority
IL
Israel
Prior art keywords
formulations
wound healing
compositions
effective amount
accelerated wound
Prior art date
Application number
IL101229A
Other languages
English (en)
Original Assignee
Biomedical Polymers Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomedical Polymers Int filed Critical Biomedical Polymers Int
Publication of IL101229A0 publication Critical patent/IL101229A0/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0009Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
    • A61L26/0028Polypeptides; Proteins; Degradation products thereof
    • A61L26/0047Specific proteins or polypeptides not covered by groups A61L26/0033 - A61L26/0042
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/65Tetracyclines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/27Growth hormone [GH], i.e. somatotropin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/28Insulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/40Transferrins, e.g. lactoferrins, ovotransferrins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Materials Engineering (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Physical Water Treatments (AREA)
IL101229A 1991-08-30 1992-03-15 Compositions for accelerated wound healing IL101229A0 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US75284991A 1991-08-30 1991-08-30

Publications (1)

Publication Number Publication Date
IL101229A0 true IL101229A0 (en) 1992-11-15

Family

ID=25028127

Family Applications (1)

Application Number Title Priority Date Filing Date
IL101229A IL101229A0 (en) 1991-08-30 1992-03-15 Compositions for accelerated wound healing

Country Status (12)

Country Link
US (1) US5461030A (de)
EP (1) EP0650366B1 (de)
JP (1) JPH06510453A (de)
AT (1) ATE186840T1 (de)
AU (1) AU670413B2 (de)
BR (1) BR9206433A (de)
CA (1) CA2116549A1 (de)
DE (1) DE69230344T2 (de)
FI (1) FI940932A (de)
HU (1) HUT67319A (de)
IL (1) IL101229A0 (de)
WO (1) WO1993004691A1 (de)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5705485A (en) * 1987-09-18 1998-01-06 Ethicon, Inc. Gel formulations containing growth factors
US5591709A (en) * 1991-08-30 1997-01-07 Life Medical Sciences, Inc. Compositions and methods for treating wounds
US20020091155A1 (en) * 1995-06-22 2002-07-11 Btg Pharmaceutical Corp. Method for ameliorating muscle weakness/wasting in a patient infected with human immunodeficiency virus-type 1
US5449522A (en) * 1993-08-24 1995-09-12 Hill; Albert F. Pharmaceutical composition for immunoenhancement therapy
US5840770A (en) * 1993-08-24 1998-11-24 Hill Medical Corporation Method of killing tumor cells
AUPM678294A0 (en) * 1994-07-13 1994-08-04 Gropep Pty Ltd Use of insulin-like growth factor in combination with insulin
ATE198039T1 (de) * 1995-01-09 2000-12-15 Thorel Jean Noel Nährstoff für epidermale zellkultur und verwendung
US5681561A (en) * 1995-06-07 1997-10-28 Life Medical Sciences, Inc. Compositions and methods for improving autologous fat grafting
US6380255B1 (en) * 1995-06-07 2002-04-30 Karo Bio Ab Treatment for dermal skin atrophy using thyroid hormone compounds or thyroid hormone-like compounds
EP1486565B1 (de) 1995-10-11 2007-11-21 Novartis Vaccines and Diagnostics, Inc. Kombinierung von PDGF, KGF, IGF und IGFBP für Wundheilung
US5783556A (en) * 1996-08-13 1998-07-21 Genentech, Inc. Formulated insulin-containing composition
US6692961B1 (en) * 1996-10-11 2004-02-17 Invitrogen Corporation Defined systems for epithelial cell culture and use thereof
ATE356198T1 (de) * 1996-10-11 2007-03-15 Invitrogen Corp Definierte systeme zur kultivieurng epithelialer zellen und anwendung derselben
US6576659B1 (en) * 1996-12-05 2003-06-10 Bio-Technology General Corp. Use of oxandrolone in the treatment of burns an other wounds
US5866546A (en) * 1997-04-18 1999-02-02 Hadasit Medical Research Services And Development Company Ltd. Treatment for diabetes
US6129817A (en) * 1997-07-10 2000-10-10 Westvaco Corporation Unified on-line/off-line paper web formation analyzer
DE19821625C1 (de) * 1998-05-15 2000-01-05 Merck Patent Gmbh Pharmazeutische Zubereitung
GB9906715D0 (en) * 1999-03-23 1999-05-19 Ferring Bv Compositions for promoting growth
GB2362100B (en) 2000-05-08 2002-05-08 Maelor Pharmaceuticals Ltd Wound gels
KR100385293B1 (ko) * 2000-05-13 2003-05-23 주식회사 리젠 바이오텍 βig-h3의 일부 도메인을 이용한 세포 부착 및 창상치유 방법
US7081240B1 (en) * 2000-06-28 2006-07-25 Zimmer Orthobiologics, Inc. Protein mixtures for wound healing
US20100129332A1 (en) * 2000-07-31 2010-05-27 Tamar Tennenbaum Methods and pharmaceutical compositions for healing wounds
US20030148924A1 (en) * 2002-07-09 2003-08-07 Tamar Tennenbaum Methods and pharmaceutical compositions of healing wounds
US20040037828A1 (en) * 2002-07-09 2004-02-26 Bar-Ilan University Methods and pharmaceutical compositions for healing wounds
AU2001284364B2 (en) * 2000-07-31 2006-09-28 Bar Ilan University Methods and pharmaceutical compositions for healing wounds
US20060258562A1 (en) * 2000-07-31 2006-11-16 Healor Ltd. Methods and pharmaceutical compositions for healing wounds
GB2369572A (en) * 2000-11-29 2002-06-05 Raft Trustees Ltd Wound treatment composition comprising insulin
US7115563B2 (en) * 2002-05-29 2006-10-03 Insignion Holding Limited Composition and its therapeutic use
GB0212405D0 (en) * 2002-05-29 2002-07-10 Insignion Holdings Ltd Composition and its therapeutic use
EP2340856B2 (de) * 2003-05-24 2017-11-15 La Prairie Group AG Kosmetische oder dermatologische Zubereitung umfassend eine Nährmedienphase
WO2005013885A2 (en) * 2003-08-07 2005-02-17 Healor Ltd. Pharmaceutical compositions and methods for accelerating wound healing
MXPA06011029A (es) * 2004-04-07 2007-01-25 Ares Trading Sa Formulacion liquida de hormona del crecimiento.
US7312198B2 (en) * 2005-07-12 2007-12-25 Essential Skincare, Llc Protein compositions for promoting wound healing and skin regeneration
WO2007026356A2 (en) 2005-08-29 2007-03-08 Healor Ltd. Methods and compositions for prevention and treatment of diabetic and aged skin
US7718170B2 (en) * 2006-08-21 2010-05-18 Essential Skincare, Llc Alkaline phosphatase compositions to reduce skin cancer
US20080098491A1 (en) * 2006-10-19 2008-04-24 Zoltan Laboratories Llc Mouse models to study cachexia
FR2907683A1 (fr) * 2006-10-27 2008-05-02 De Potter Philippe Viseux Composition medicale pour cicatrisation des plaies et pansements permettant son application
KR20100040912A (ko) * 2007-07-30 2010-04-21 힐로 리미티드 약제학적 조성물 및 관련 방법
EP2234653B1 (de) 2008-01-17 2014-07-30 First Water Limited Hydrogel-copolymer-zusammensetzung und verwendungen davon, z. b. als wundverband
KR20130095835A (ko) * 2009-02-24 2013-08-28 힐로 리미티드 여드름 및 기타 질환 치료용 비스파틴 치료제
GB0905290D0 (en) 2009-03-27 2009-05-13 First Water Ltd Multilayer compositions and dressings
WO2011083483A2 (en) 2010-01-11 2011-07-14 Healor Ltd. Method for treatment of inflammatory disease and disorder
US9474685B2 (en) 2011-09-28 2016-10-25 Sure-Shot Medical Device Inc. Apparatus for localized dermatological treatment
WO2013187899A1 (en) * 2012-06-14 2013-12-19 Ella Lindenbaum Compositions and methods for stimulating wound healing
US11432990B2 (en) 2013-08-30 2022-09-06 ISOS Solutions, LLC Textured apparatus with therapeutic material incorporated therein and methods of manufacturing same
GB201318842D0 (en) 2013-10-24 2013-12-11 First Water Ltd Flexible hydrogel wound dressings
US20220111111A1 (en) 2019-01-17 2022-04-14 Scapa Tapes Na Composition for use in wound dressings
IT201900022803A1 (it) * 2019-12-03 2021-06-03 Univ Degli Studi Di Ferrara Gel di alginato per la medicazione di ferite cutanee

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3664925A (en) * 1970-02-20 1972-05-23 Martin Sonenberg Clinically active bovine growth hormone fraction
US3904753A (en) * 1970-02-20 1975-09-09 Research Corp Clinically active bovine growth hormone fraction
US4342832A (en) * 1979-07-05 1982-08-03 Genentech, Inc. Method of constructing a replicable cloning vehicle having quasi-synthetic genes
HU195618B (en) * 1981-03-17 1988-06-28 Human Oltoanyagtermelo Process for producing composition for treating epidermic lesions of skin
US4863899A (en) * 1983-05-09 1989-09-05 Todaro George J Biologically active polypeptides
US4444760A (en) * 1983-06-17 1984-04-24 Merck & Co., Inc. Purification and characterization of a protein fibroblast growth factor
US4673649A (en) * 1983-07-15 1987-06-16 University Patents, Inc. Process and defined medium for growth of human epidermal keratinocyte cells
US4940666A (en) * 1983-07-15 1990-07-10 University Patents, Inc. Process and defined medium for growth of human epidermal keratinocyte cells
US5165938A (en) * 1984-11-29 1992-11-24 Regents Of The University Of Minnesota Wound healing agents derived from platelets
US4696917A (en) * 1985-08-01 1987-09-29 Lindstrom Richard L Irrigation solution
US4886786A (en) * 1985-08-01 1989-12-12 Lindstrom Richard L Additive for irrigation solution or surgical solution
NZ226170A (en) * 1987-09-18 1990-07-26 Ethicon Inc Stable freeze-dried pharmaceutical composition containing epidermal growth factor
US5034375A (en) * 1988-08-10 1991-07-23 Institute Of Molecular Biology, Inc. Process of wound healing using PDGF and EGF
GB8823649D0 (en) * 1988-10-07 1988-11-16 Geistlich Soehne Ag Chemical compounds
US5036046A (en) * 1988-10-12 1991-07-30 Eye Research Institute Of Retina Foundation, Inc. Method for enhancing healing of corneal endothelial wounds
US5051443A (en) * 1988-10-12 1991-09-24 Eye Research Institute Of Retina Foundation, Inc. Method for enhancing healing of corneal endothelial wounds
US5013714A (en) * 1988-12-15 1991-05-07 Lindstrom Richard L Viscoelastic solution
US5204325A (en) * 1988-12-15 1993-04-20 Lindstrom Richard L Viscoelastic solution
US5218093A (en) * 1989-03-01 1993-06-08 Allelix Biopharmaceuticals, Inc. EGF variants and pharmaceutical use thereof
US5219739A (en) * 1989-07-27 1993-06-15 Scios Nova Inc. DNA sequences encoding bVEGF120 and hVEGF121 and methods for the production of bovine and human vascular endothelial cell growth factors, bVEGF120 and hVEGF121
US5035887A (en) * 1989-09-07 1991-07-30 Institute Of Moelcular Biology, Inc. Wound healing composition of IL-1 and PDGF or IGF-1
US5056520A (en) * 1989-10-11 1991-10-15 Medex, Inc. Probe for blood gas sensing
EP0516901A1 (de) * 1991-06-06 1992-12-09 Richard L. Lindstrom Methode und Einrichtung für serumlose medizinische Lösung

Also Published As

Publication number Publication date
JPH06510453A (ja) 1994-11-24
BR9206433A (pt) 1994-09-27
CA2116549A1 (en) 1993-03-18
US5461030A (en) 1995-10-24
HUT67319A (en) 1995-03-28
DE69230344T2 (de) 2000-04-13
AU2587992A (en) 1993-04-05
FI940932A0 (fi) 1994-02-28
EP0650366B1 (de) 1999-11-24
AU670413B2 (en) 1996-07-18
WO1993004691A1 (en) 1993-03-18
HU9400593D0 (en) 1994-05-30
DE69230344D1 (de) 1999-12-30
FI940932A (fi) 1994-02-28
EP0650366A4 (de) 1994-12-20
ATE186840T1 (de) 1999-12-15
EP0650366A1 (de) 1995-05-03

Similar Documents

Publication Publication Date Title
IL101229A0 (en) Compositions for accelerated wound healing
NZ227788A (en) Peptide having growth hormone regulatory effects, and compositions
AU585268B2 (en) Inductive collagen based bone repair preparations
MX9705710A (es) Compuestos con propiedades de liberacion de la hormona del crecimiento.
RU94046291A (ru) Способ профилактики и лечения периферической невропатии, композиция, содержащая инсулин-подобный фактор роста i
AU644610B2 (en) Synergistic microbicidal combinations
IL106248A0 (en) Adhesive compositions and method
MY103518A (en) Steroid 5- -reductase inhibitors
BG102708A (en) 4-aminopyrimidine derivatives, medicamentous preparations containing them, their application and method for their preparation
CA2159449A1 (en) Oesteoblast Growth Stimulating Composition Containing PDGF and Vitamin D
DE69510775D1 (de) Methoden zur verwendung von cyclischenpolyanionischen polyderivatenzur kontrolle von hautfalten
ATE55695T1 (de) Verwendung von defibrotid zur herstellung pharmazeutischer zusammensetzungen zur behandlung peripherer arteriopathien.
ES2071080T3 (es) Igf-i para tratar el efecto adverso de la terapia con esteroides.
TW272128B (de)
DE3062238D1 (en) Method for enhancing growth rate and feed efficiency of ruminants
IT1261048B (it) Composizione per accelerare la rimarginazione di ferite
EP0925064A4 (de) 5-ANDROSTEN 3-beta, 17-alpha DIOL ALS TUMORWACHSTUMSHEMMER
NO940406L (no) Preparat og fremgangsmåte for behandling av sårskader
MD950100A (en) Substituted oximethers method of their preparation and application for pests and fungus control
UA15363A (uk) Засіб для лікуваhhя відкритих пошкоджеhь
SU1453860A1 (ru) Аддукты трис-гексафторацетилацетонатов лантаноидов с трифенилфосфиноксидом в качестве активной добавки к полимерным материалам, трансформирующим ультрафиолетовое излучение в видимую область спектра
CS275008B2 (en) 2 alpha,3 alpha-dihydroxy-17 beta-(2-methyl-butyryloxy) -7-oxo-b-homo-androstane-6-on and method of its preparation
UA31299A (uk) Спосіб лікування хронічного післятравматичного остеомієліту
SU1471341A1 (ru) Состав для регулирования роста облепихи
MY107387A (en) Aromatic steroid 5-(alpha)-reductase inhibitors.